Dr. Traci N. Bethea is an Assistant Professor in the Office of Minority Health and Health Disparities Research and the Cancer Prevention and Control Program at Georgetown Lombardi Comprehensive Cancer Center. Her research focuses on chemical and non-chemical stressors underlying cancer health disparities affecting Black women. Her current work examines environmental exposures and other risk factors for accelerated aging among breast cancer survivors, risk factors for ovarian cancer incidence and survival, and the health effects of sleep disturbances. Her research on modifiable factors and breast cancer survivorship among Black women is supported by a career development award from the National Cancer Institute. New research directions involve the development and testing of interventions targeting environmental, social, and/or clinical factors in order to reduce cancer health disparities and aims to apply a cells-to-society lens for actionable research leveraging relationships between the biologic, individual, and macroenvironmental levels. Dr. Bethea’s research program also seeks to incorporate stakeholder perspectives and to engage minoritized scholars through ongoing education, outreach, and research translation activities. Dr. Bethea received a PhD in Environmental Health from Boston University School of Public Health and completed postdoctoral training in cancer epidemiology with the Black Women’s Health Study at the Slone Epidemiology Center at Boston University.
Eboneé N. Butler, PhD, MPH is an assistant professor of cancer epidemiology at the UNC Gillings School of Global Public Health and is a co-leader of the National Cancer Institute’s Prostate Cancer Cohort Consortium (PC3) working group. Her line of research examines novel exposures that may be linked to prostate cancer etiology, using classical epidemiologic study designs and healthcare administrative claims. Her work also centers on cancer health equity, as she seeks to understand how interactions with healthcare systems influence tumor biology. For her tumor-based work, she focuses on identifying molecular and morphologic features in prostate tissues that have etiologic or prognostic utility, with the goal of eliminating race disparities in prostate cancer incidence and mortality.
Dr. Cerhan is a Professor of Epidemiology and the Ralph S. and Beverly Caulkins Professor of Cancer Research in the Department of Quantitative Health Sciences, Mayo Clinic College of Medicine & Science, Rochester, Minnesota. He received a B.S. degree in Anthropology in 1986, a Ph.D. degree in Epidemiology in 1991, and a M.D. in 1993, all from the University of Iowa. He also completed a post-doctoral fellowship in cancer epidemiology at the University of Minnesota School of Public Health. Dr. Cerhan joined Mayo in 1998, and is currently Enterprise Deputy Director for Population Sciences and Cancer Control in the Mayo Clinic Comprehensive Cancer Center and co-director of the Biorepositories Program in Mayo Clinic Center for Individualized Medicine. His research program has been continuously funded by the National Institutes of Health since 1995, and is focused on understanding the role of environmental, lifestyle, genetic and biologic factors in the etiology of lymphomas and the role of lifestyle, genetic, tumor/microenvironment and treatment factors in prognosis and survivorship of lymphoma patients. He currently leads the Lymphoma Epidemiology of Outcomes (LEO) cohort, a NIH-funded cohort study involving eight US academic centers. He collaborates internationally, and he has served in many leadership roles in the International Lymphoma Epidemiology (InterLymph) Consortium and the National Cancer Institute Cohort Consortium.
Dr. Stephen Chanock is the Director of the NCI Division of Cancer Epidemiology and Genetics (DCEG). He is a leading expert in the discovery and characterization of cancer susceptibility regions in the human genome. He has received numerous awards for his scientific contributions to our understanding of common inherited genetic variants associated with cancer risk and outcomes. Dr. Chanock received his M.D. from Harvard Medical School and completed clinical training in pediatrics, pediatric infectious diseases, and pediatric hematology/oncology and research training in molecular genetics at Boston Children’s Hospital and the Dana-Farber Cancer Institute, Boston. From 2001-2007, he was a tenured investigator in the Genomic Variation Section of the Pediatric Oncology Branch in the NCI Center for Cancer Research. He also served as co-chair of NCI's Genetics, Genomics and Proteomics Faculty for five years. In 2001, he was appointed as Chief of the Cancer Genomics Research Laboratory (formerly Core Genotyping Facility), and in 2007 as Chief of the Laboratory of Translational Genomics, both within DCEG. From 2012 to 2013, he also served as Acting Co-Director of the NCI Center for Cancer Genomics. Dr. Chanock was appointed Director of DCEG in August 2013. Since 1995, Dr. Chanock has served as the Medical Director for Camp Fantastic, a week-long recreational camp for pediatric cancer patients, which is a joint venture of the NCI and Special Love, Inc.
Castine Clerkin is the Program Manager for NAACCR’s Virtual Pooled Registry Cancer Linkage System. In this role she oversees all aspects of the project, from pilot linkages to workgroup calls to system development, testing, and implementation. Prior to joining NAACCR, Castine was a Program Consultant with CDC’s National Program of Cancer Registries for over 7 years and led various special projects, including early case capture of childhood cancer cases. Castine began her career in cancer surveillance in 2001, working as the epidemiologist and data manager for the Maine Cancer Registry.
I am the newly appointed Director of the Susan G. Komen Tissue Bank (KTB), a tenured Professor at Indiana University in the Fairbanks School of Public Health, and a Scientific Member in the Cancer Prevention and Control Program at Indiana University Melvin and Bren Simon Comprehensive Cancer Center. My research focus is on genetic and molecular factors in female cancers that impact disease incidence or prognosis in underserved populations. Currently, I am PI of a NCI R01 to examine molecular alterations in high grade endometrial cancers and am actively engaged in analyzing data and biospecimens from African American women with benign breast disease (BBD) and subsequent invasive cancers. I have an strong history of successful national and international research collaborations, in breast, endometrial, ovarian, and lung cancers.
Joanne Elena, Ph.D., M.P.H., is an Epidemiologist and Program Director in the Clinical and Translational Epidemiology Branch of the Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). She is responsible for developing, managing, and promoting a research portfolio of grants focused on diet and lifestyle factors that influence cancer progression, subsequent primary cancers, recurrence, and survival. She is also involved in optimizing the use and design of cohort studies, incorporating new technologies to assess exposures and outcomes, maximizing the use of existing data, and manages several funding announcements that support infrastructure needs for large cohort studies. She serves as the Scientific Director for NCI’s Cohort Consortium and is EGRP’s co-coordinator for cohort activities.
Dr. Elena completed her Ph.D. in nutritional epidemiology at the University of North Carolina at Chapel Hill and her M.P.H. at the Johns Hopkins Bloomberg School of Public Health.
Dr. Heather Eliassen is Professor of Nutrition and Epidemiology at the Harvard T.H. Chan School of Public Health and Associate Professor of Medicine and Epidemiology at Harvard Medical School. She is Associate Director of the Channing Division of Network Medicine and Director of the Chronic Disease Epidemiology Unit. Dr. Eliassen is co-PI of two ongoing prospective cohort studies, the Nurses’ Health Study (NHS), founded in 1976 with 121,700 women, and the Nurses’ Health Study II (NHSII), founded in 1989 with 116,400 women. She also is Director of the BWH/Harvard Cohort Biorepository, which houses more than three million biospecimens from 200,000 cohort participants, and Co-Leader of the Cancer Epidemiology Program at the Dana Farber/Harvard Cancer Center. She serves as Chair of the NCI Cohort Consortium Steering Committee. Her research focuses on the etiology of breast cancer, examining associations between lifestyle factors, biomarkers of lifestyle and hormones, and breast cancer risk and progression. Dr. Eliassen is actively involved in the teaching and mentoring of graduate students at the Harvard T.H. Chan School of Public Health, and mentoring of postdoctoral fellows and junior faculty members at Harvard and Brigham and Women’s Hospital.
Patricia A. Ganz, M.D., is a medical oncologist and Distinguished Professor of Health Policy & Management AND Medicine at the UCLA Schools of Public Health and Medicine. She is also the Associate Director for Population Science at the UCLA Jonsson Comprehensive Cancer Center. In 1999 she was awarded an American Cancer Society Clinical Research Professorship for “Enhancing Patient Outcomes across the Cancer Control Continuum.” Dr. Ganz was elected to the Institute of Medicine (IOM) in 2007, now National Academy of Medicine (NAM). She served on the National Cancer Institute Board of Scientific Advisors from 2002-2007 and on the American Society of Clinical Oncology (ASCO) Board of Directors from 2003-2006. She received the American Cancer Society Medal of Honor in 2010. Dr. Ganz has served on four NAM consensus committees: From Cancer Patient to Cancer Survivor, 2005; Cancer Care for the Whole Patient, 2008; Delivering High-quality Cancer Care, 2013; Diagnosing and Treating Adult Cancers and Associated Impairments, 2021. Dr. Ganz is a pioneer in the assessment of quality of life in cancer patients, and has focused much of her clinical and research efforts in the areas of breast cancer and its prevention. At the Jonsson Comprehensive Cancer Center, she leads Cancer Control and Survivorship Program. Her major areas of research include cancer survivorship and the late effects of cancer treatment, measurement of patient reported outcomes in clinical treatment trials, and quality of care for cancer patients. Dr. Ganz is Editor-in-Chief of the Journal of the National Cancer Institute (JNCI).
Dr. Mia Gaudet is the Chief Scientist for the Connect for Cancer Prevention Cohort study in the National Cancer Institute Division of Cancer Epidemiology and Genetics (DCEG) Trans-Divisional Research Program. In this role, Dr. Gaudet oversees cohort management and activities as well as serves as the study’s chair in the Executive and DCEG Steering Committees. Previously, Dr. Gaudet was a Scientific Director of Epidemiology Research at the American Cancer Society (ACS). In the ACS Cancer Prevention Studies, she contributed to cohort activities, including participant recruitment and retention, questionnaire development, and resource utilization. In addition, she initiated and oversaw the collection and characterization of breast and ovarian tissue from women diagnosed with these cancers in these cohorts. She conducted research to clarify and identify genetic and non-genetic risk factors for subtypes of breast cancer with an emphasis on more fatal subtypes in the Cancer Prevention Study cohorts and other collaborative efforts. In addition, Dr. Gaudet has held academic positions at Rollins School of Public Health at Emory University, Memorial Sloan-Kettering, and Albert Einstein College of Medicine. She is the author of over 200 scientific articles and has co-authored “Genetic Epidemiology of Breast Cancer” in Women & Health (2013) and “Breast Cancer Epidemiology” in the 4th edition of Cancer Epidemiology and Prevention (2017), a premier reference text in cancer epidemiology. Dr. Gaudet obtained her doctoral degree in epidemiology at the University of North Carolina at Chapel Hill. She completed a postdoctoral fellowship in DCEG.
Geoffrey Ginsburg, M.D., Ph.D., is the Chief Medical and Scientific Officer of the All of Us Research Program at the National Institutes of Health. He leads the Division of Medical and Scientific Research and is responsible for helping to set the scientific vision and strategy for the program. He also oversees the program’s collection and curation of data, and integration of new data types to support a wide range of impactful scientific discoveries. Prior to joining All of Us, Ginsburg was founding director for the Center for Applied Genomics & Precision Medicine in the Duke University School of Medicine where he pioneered translational genomics and the development of novel diagnostics. At Duke, he was professor of medicine, biostatistics and bioinformatics, pathology, and biomedical engineering. He also was a professor in the School of Nursing; he will remain adjunct professor of medicine. He has held senior leadership roles at Millennium Pharmaceuticals Inc. and was a member of the Harvard Medical School faculty. At NIH, Ginsburg has served on the board of external experts for the National Heart, Lung, Blood Institute, as an advisory council member to the National Human Genome Research Institute and the National Centers for Advancing Translational Sciences, and most recently on the Advisory Committee of the Director of NIH. He received his M.D. and Ph.D. in biophysics from Boston University and completed an internal medicine residency at Beth Israel Hospital in Boston.
Dr. Katrina Goddard was appointed Director of the Division of Cancer Control and Population Sciences (DCCPS) in October 2021. In this position, she oversees a division that covers a wide range of scientific domains and disciplines, including epidemiology, behavioral science, surveillance and statistics, cancer survivorship, and health services and outcomes research.
Prior to joining NCI, Dr. Goddard was a Distinguished Investigator and Director of Translational and Applied Genomics at the Kaiser Permanente Center for Health Research (CHR) in Portland, OR. Before joining CHR in 2007, she was faculty in the Department of Epidemiology and Biostatistics (now Population and Quantitative Health Sciences) at Case Western Reserve University in Cleveland, OH. She was also a mid-career fellow at the Centers for Disease Control and Prevention in Genetics & Public Health Research and Practice.
Dr. Nonye Harvey is a Health Science Policy Analyst in the NIH Genomic Data Sharing Implementation Office housed within the Immediate Office of the Director, Office of Extramural Research (OER), NIH Office of the Director. She works on several trans-NIH groups and committees to facilitate central coordination and implementation of NIH data sharing policies, and the harmonization and standardization of systems and processes across the data sharing ecosystem. Previously, Dr. Harvey held various positions and roles at NCI / EGRP where she served as the Executive Director of the NCI Cohort Consortium from 2006-2020, and managed cancer epidemiology cohort research and consortia. Prior to joining NCI, Dr. Harvey served as the Program Manager of the Mid-Atlantic Region Pediatric Environmental Health Specialty Unit where she worked on children’s environmental health research and developed healthcare provider training programs. She earned her M.P.H. from the GWU Milken Institute School of Public Health and her Dr.P.H. from the University of Illinois at Chicago School of Public Health.
Dr. Kathy Helzlsouer serves as Associate Director of the Epidemiology and Genomics Research Program and chief medical officer for the National Cancer Institute's (NCI) Division of Cancer Control and Population Sciences. Dr. Helzlsouer is board certified in internal medicine and medical oncology. She earned her medical degree from the University of Pittsburgh and has received postgraduate education and training in internal medicine, oncology, and epidemiology at the University of Virginia and the Johns Hopkins University. Prior to joining NCI, Dr. Helzlsouer was a professor in the Department of Epidemiology at the Johns Hopkins University Bloomberg School of Public Health and established the Prevention and Research Center at an academic community hospital. Dr. Helzlsouer’s research experience and clinical activities include cancer epidemiology and prevention, cancer risk assessment, cancer survivorship, cohort studies and clinical trials.
Sarah S. Jackson (she/her) earned her Ph.D. in epidemiology at the University of Maryland, Baltimore. She joined the Infections and Immunoepidemiology Branch (IIB) in 2018 as a postdoctoral fellow. In 2021, she was inducted into the NIH Independent Research Scholar Program and subsequently was promoted to research fellow. Dr. Jackson’s research interests include sex differences in cancer incidence and cancer risk and outcomes among transgender and non-binary individuals. She is co-chair of the NIH Sexual and Gender Minority Scientific Interest Group and the founder and chair of the Sexual and Gender Minority Interest Group within the NCI Cohort Consortium. In both these roles, she seeks to increase the collection of data on sexual orientation and gender identity.
Dr Mattias Johansson is a molecular epidemiologist working at the International Agency for Research on Cancer (IARC/WHO). He attained his PhD in 2008 from Umeå University in Sweden. At IARC, he co-leads the Integrative Epidemiology Team within the Genomic Epidemiology Branch.
Dr Johansson has a broad research agenda focusing on multiple cancer sites with two overarching aims; i) to elucidate etiological factors of cancer risk and survival, and ii) to develop accurate prediction models for early detection and prognostics. These studies integrate information from questionnaire, demographic, biomarker, genetic and genomic data, and are typically conducted in close collaboration with investigators from around world.
Dr Johansson has extensive experience in conducting research within prospective cohorts and is affiliated with the European Prospective Investigation into Cancer and nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS). He has coordinated the Lung cancer Cohort Consortium (LC3) since its inception in 2010 over several rounds of funding.
During the meeting Dr Johansson will talk about his experience in developing risk prediction biomarkers for lung cancer within the LC3 consortium.
I am a Professor of Epidemiology and Biostatistics, interested in the genetic epidemiology of complex diseases generally, and cancer genetics and genomics particularly. My current research projects include the development, evaluation and implementation of multifactoral risk models for complex diseases, including breast cancer; studying the links between inherited germline variation and prediagnostic exposures and tumor mutational profiles; and understanding the shared genetic contributions to multiple cancers and other complex traits.
Larry Kushi is a cancer and nutritional epidemiologist whose research is focused primarily on cancer outcomes and cancer care delivery research. He is currently multiple PI of several NCI-supported research projects include the Pathways Study, a prospective cohort study investigating multi-level factors in breast cancer outcomes and supported through the NCI’s cancer epidemiology cohort infrastructure program; two Pathways-adjacent projects, including a study on the role of breast white adipose tissue inflammation and related metabolic parameters on breast cancer outcomes, and an investigation into reasons underlying the breast cancer survival advantage of Asian Americans; a project examining racial and ethnic disparities in ovarian cancer outcomes; and a P01 focused on cancer care and outcomes among adolescents and young adults diagnosed with cancer. He also co-leads a grant on the evolution of the COVID-19 pandemic and serological surveillance in the Kaiser Permanente Northern California (KPNC) health system, part of the NCI’s Serological Sciences Network for COVID-19. He was PI of the NCI-funded Cancer Research Network (CRN), providing infrastructure support for cancer research in a nationwide consortium of health care systems. The CRN developed one of the first common data models for research, known as the Virtual Data Warehouse (VDW). A graduate of Amherst College and the Harvard School of Public Health, Larry was previously at the Fred Hutchinson Cancer Research Center, the University of Minnesota, and Columbia University where he was the Vahlteich Professor in Nutrition. In 2002, he joined the Division of Research, KPNC, where he is Director of Scientific Policy.
Dr Macklin-Doherty is a medical oncologist working at The Royal Marsden Hospital, London, UK. She has a clinical interest in the acute management of patients with Lymphoma as well as the management of cancer survivors of a range of tumour types, and a research interest in the study of long-term side effects of a range of cancer treatments. She undertook her PhD under Professor Anthony Swerdlow at the Institute of Cancer Research, where she expanded a national cohort study investigating breast cancer risk after radiotherapy in ~8,000 young women treated for Hodgkin Lymphoma with up to 60 years follow up. This cohort has built a valuable resource of questionnaire and clinical data, linked to national datasets, as well as blood and tissue samples to address key questions about radiation-related breast cancer risk. She is currently an NIHR funded post-doctoral fellow and is investigating risks of a range of second cancers after Lymphoma treatments as well as other key late effects such as hospital admissions and admission-related diagnoses. She is also interested in investigating late effects of more modern treatments for melanoma.
She is keen to collaborate with others with similar interests, and pool resources to answer questions about long-term late effect risks. She would ultimately like to translate risk profiles to inform development of risk-prediction models for a range of late effects for use within patient clinics.
Dr. Lauren E. McCullough is Associate Professor in the Department of Epidemiology at the Rollins School of Public Health. She earned her BA from Vanderbilt University, MSPH from Meharry Medical College, and PhD in Epidemiology from the University of North Carolina at Chapel Hill. Dr. McCullough's overarching research interests are in cancer epidemiology, specifically the contributions of obesity and the social environment to the tumor epigenome and microenvironment, as well as disparities in cancer outcomes. Her research program integrates molecular epidemiology, epigenetics, and other biomarkers for disease risk and progression; environmental and social epidemiology; and causal inference methods. Her research goals are to improve cancer outcomes in underserved populations by bridging molecular and social epidemiology to identifying targets for pharmacologic, behavioral, and policy intervention.
Roger is an epidemiologist with expertise in international collaboration and the analysis of genetic and lifestyle data from observational studies. He joined Cancer Council Victoria in 2013 and was appointed the Cancer Epidemiology Division’s Head in 2017. He is Chief Investigator of the Melbourne Collaborative Cohort Study (Health 2020) and the Australian Breakthrough Cancer Study. He was Chair of the NCI Cohort Consortium Steering Committee in 2021.
Roger’s work focuses on cancer epidemiology, including genetic and lifestyle-related risk factors, genetic and gene-environment interactions and DNA methylation. He currently holds a World Cancer Research Fund grant to use NCI Cohort Consortium data to establish dietary and body size-related risk factors for bladder cancer.
Erika Rees-Punia, Ph.D., MPH is a senior principal scientist for the American Cancer Society. Dr. Rees-Punia is an exercise physiologist by training and leads research on the promotion and benefits of physical activity in cancer survivors. She leads a randomized exercise trial embedded within the Cancer Prevention Study-3 (CPS-3), co-leads the CPS-3 Medicare linkage, and co-leads the CPS-3 Accelerometer Sub-Study, with the goal of collecting waist-worn accelerometer data on 20,000 participants. With NCI cohort consortium, she co-leads the Physical Activity Pooling Project Workgroup and is a part of the Associate Member Council. Dr. Rees-Punia finished her PhD in 2018 at the University of Georgia.
Dr. Jeannette M. Schenk is a Senior Staff Scientist in the Cancer Prevention Program at the Fred Hutchinson Cancer Center (FHCC). She received a B.S. in molecular biology from University of California San Diego, a M.S. in Clinical Nutrition from New York University and a Ph.D. in epidemiology from University of Washington. Dr. Schenk’s research is focuses on the associations of diet, obesity, lifestyle factors and metabolic biomarkers with prostate cancer incidence and progression. She serves as Co-Investigator on two UM1 grants for the Prostate Cancer Prevention Trial (PCPT) and Selenium and Vitamin E Cancer Trial (SELECT) cohorts UM1 (CA182883) and the Prostate Cancer Active Surveillance Study (PASS) cohort UM1 (CA224255). Given her institutional location, Dr. Schenk also has established relationships with other Fred Hutch Consortium cohorts such as CARET and WHI.
Sheri Schully, Ph.D., is the deputy chief medical and scientific officer of the All of Us Research Program. In this role, she is helping to set the scientific vision and strategy for the program as well as overseeing the establishment of Ancillary Studies. Prior to this role, she was a team lead and senior advisor for disease prevention in the Office of Disease Prevention (ODP). There, she led the effort to systematically monitor NIH investments in prevention research and assess the progress of that research. She also served as the team lead for the Knowledge Integration Team as well as a program officer in the Epidemiology and Genomics Research Program at the National Cancer Institute (NCI). She came to NCI as a Presidential Management Fellow in 2005.
Dr. Schully earned both a Ph.D. in biological sciences with a concentration in population genetics and a B.S. in zoology with a minor in chemistry from Louisiana State University.
Dr. V. Wendy Setiawan is Professor of Population and Public Health Sciences, Professor of Medicine and the Jane and Kris Popovich Cancer Research Chair at USC Keck School of Medicine. She is a Co-Leader of the Cancer Epidemiology Program in the Norris Comprehensive Cancer Center and the Associate Director for Population Sciences in the USC Research Center for Liver Diseases. Dr. Setiawan is a cancer epidemiologist focusing on understanding the determinants of ethnic differences in cancer incidence and mortality and identifying populations at highest risk because of biologic factors and environmental exposures. Her research goal is to identify effective modalities for disease prevention for population at risk and ultimately reduce cancer health disparities. Her primary research interest in cancer study is focused on pancreatic, liver, and endometrial cancer.
Dr. Setiawan has been leading many epidemiologic studies including the Multiethnic Cohort Study and the NCI Epidemiology of Endometrial Cancer Consortium (E2C2). She is currently Principal Investigator of four active NCI and NIMHD-funded R01s and co-investigator of several NIH grants. Her studies utilize multi-level data integration encompassing genetics, biomarkers, lifestyle, and social/contextual factors to elucidate factors associated with differences in cancer incidence and outcome across ethnic groups. She has published >170 peer-reviewed papers, book chapters and review articles. She currently serves on the JNCI editorial board and she is a standing member of the NCI Career Development (K award) study section.
Dr. Konrad Stopsack is a molecular and clinical epidemiologist with a focus on cancer epidemiology and a background as an internal medicine physician. His applied research aims to improve primary, secondary, and tertiary prevention of cancer through a better understanding of how and in whom potentially modifiable exposures shape tumor genomes and cancer outcomes. His multidisciplinary work builds on prospective cohort studies and hospital-based studies. He co-leads the Prostate Cancer Cohort Consortium (PC3) working group within the NCI Cohort Consortium.
Emily S. Tonorezos, MD, MPH, serves as director of the Office of Cancer Survivorship, part of the Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI). Dr. Tonorezos came to NCI from Memorial Sloan Kettering Cancer Center and the Weill Cornell Medical College, both in New York, NY, where she served as director of the Adult Long-Term Follow-Up Program for survivors of childhood and young adult cancers. Her research, which has been funded by the National Cancer Institute, the American Cancer Society, the American Institute of Cancer Research, and others, focuses on cardiometabolic consequences of cancer therapy, childhood and young adult cancer survivorship, diet and nutrition, and care coordination for this population. Dr. Tonorezos earned her medical degree from the University of Rochester School of Medicine and a Master of Public Health from the Johns Hopkins Bloomberg School of Public Health. She completed internal medicine residency and chief residency at Columbia University Medical Center, as well as a general internal medicine fellowship at the Johns Hopkins Hospital.
Dr. Cornelia Ulrich is the Executive Director of the Comprehensive Cancer Center at Huntsman Cancer Institute (HCI). She is also a Jon M. and Karen Huntsman Presidential Professor in Cancer Research in the Department of Population Health Sciences at the University of Utah. As Chief Scientific Officer and Cancer Center Executive Director, Dr. Ulrich oversees HCI’s academic consortium of more than 230 cancer research teams. She is a cancer epidemiologist whose research focuses on lifestyle and biologic factors in cancer prevention and cancer prognosis. Dr. Ulrich leads an interdisciplinary team of scientists on research related to the prevention, epidemiology, prognosis, and survivorship of cancer (ColoCare Study U01).
Ulrich’s lab has performed landmark research on colorectal cancer prevention and survivorship, including studies on biomarkers, aspirin and connections between obesity and physical activity in cancer prevention and survivorship. She has conducted several clinical trials, is the author of over 420 publications, and has served as principal investigator on more than 23 competitively funded research studies and clinical trials. She is a former Fulbright scholar, an elected member of the Board of the American Association of Cancer Institutes (AACI) and the European Academy of Cancer Sciences, a member of the Executive Leadership in Academic Medicine (ELAM) program, and serves on numerous editorial boards and advisory boards for agencies such as the National Institutes of Health (NIH), AACI, National Academies of Sciences and Medicine (NASEM), International Agency for Research on Cancer (IARC), and the American Association for Cancer Research (AACR).
Kristin Waite is a classically trained biochemist with training and laboratory experience in cellular signaling, lipid metabolism, molecular oncology, proteomics and genomics. She received her PhD in Biochemistry from Wake Forest University investigating the signaling mechanisms involved in the activation of NADPH Oxidase and completed her post-doctoral fellowship in lipid metabolism and lipid signaling at the University of Alberta in Edmonton, Canada. After her fellowship she worked in the cancer signaling field at Ohio State University and the Cleveland Clinic before moving into cancer administration at the Case Comprehensive Cancer Center. Dr. Waite moved back into the research arena, working with Dr. Jill Barnholtz-Sloan at Case Western Reserve in investigating the the etiology of brain tumors and the elucidating the mechanisms of sex-differences in glioma. She joined the National Cancer Institute (NCI) in the Division of Cancer Epidemiology and Genetics (DCEG) as a Contractor with the Dr. Barnholtz-Sloan's in the summer of 2021.